Trial Profile
Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Feb 2024
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Interferon alpha-2b (Primary) ; Paclitaxel (Primary) ; Rintatolimod (Primary)
- Indications Advanced breast cancer; Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- 11 Sep 2023 Results published in the ClinicalTrials.gov Trial Registry
- 11 Sep 2023 Results published in the AIM ImmunoTech Media Release
- 12 Jun 2023 According to a AIM ImmunoTech media release, currently data analysis is ongoing and full study results publication are expected before the end of the year.